Ameriprise
DSGN icon

Ameriprise’s Design Therapeutics DSGN Stock Holding History

Ameriprise’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Sell
34,990
-123,393
-78% -$1.25M ﹤0.01% 3691
2025
Q4 		$1.49M Buy
+158,383
New +$1.24M ﹤0.01% 3156
2024
Q4 		– Sell
-43,245
Closed -$233K – 4103
2024
Q3 		$233K Sell
43,245
-7,270
-14% -$34.2K ﹤0.01% 3713
2024
Q2 		$169K Hold
50,515
– – ﹤0.01% 3713
2024
Q1 		$204K Sell
50,515
-2,500
-5% -$6.68K ﹤0.01% 3690
2023
Q4 		$140K Buy
+53,015
New +$121K ﹤0.01% 3775

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise's DSGN Position: Q1 2026 in Review

Ameriprise reduced its Design Therapeutics (DSGN) stake by 78% in Q1 2026, selling an estimated $1.25M and leaving 34,990 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

Ameriprise first reported a position in DSGN in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.49M in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Ameriprise held 34,990 shares of Design Therapeutics worth $372K as of Q1 2026.
  • Ameriprise sold 123,393 Design Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Design Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3691 holding.
  • Ameriprise first reported a position in Design Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Ameriprise's Design Therapeutics position peaked at $1.49M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.